Biomatrix (BXM) Looking Great Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biomatrix (BXM) Looking Great

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (561)	3/20/2000 3:38:00 PM
From: JMarcus	Read Replies (2) of 569

Rick, the news from CLTX is all the more impressive because just last week CHIR announced that it was abandoning its competing product. biz.yahoo.com I recall seeing another competitor announce the abandonment of its competing product a couple months ago, but I can't recall the details. I went long CLTX after its last Informed Investors Forum presentation. I cornered the presenter after his formal remarks. He said that the uptake of the adenoviral vector had been terrific and that there appeared to be no problems with adverse side effects. Although CLTX's preclinical results with pigs had been phenomenal, I was worried about the human trials in light of other failures in the area of angiogenesis therapy for coronary disease. Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next